Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-681-1 | CAS number: 98-56-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
PCBTF is practically non-toxic to laboratory animals after acute exposure via oral, dermal or inhalatory administration.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- September - October 1976
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: NON GLP, no guideline reported.
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Please refer to the Executive Summary for details on method.
- GLP compliance:
- no
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 121-148 g
- Housing: plastic cages on sawdust
- Fasting: no food since 16 hs before treatment
- Diet : ALTROMIN 1324 ad libitum
- Water: ad libitum
IN-LIFE DATES: From: 28 September To: 12 October - Route of administration:
- oral: gavage
- Vehicle:
- vegetable oil
- Remarks:
- sesam oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 25%
MAXIMUM DOSE VOLUME APPLIED: 10.000 mg/kg - Doses:
- 4000, 6300, 10000 mg/kg
- No. of animals per sex per dose:
- 10 (males)
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs. - Statistics:
- Probit analysis
- Preliminary study:
- No
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 5 546 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- > 4 575 - < 6 724
- Mortality:
- 4000 mg/kg: 1/10 rat
6300 mg/kg: 8/10 rat
10000 mg/kg: 9/10 rat - Clinical signs:
- convulsions, loss of balance,
- Gross pathology:
- whitish mucosa in the small intestine
- Other findings:
- No finding in macroscopic evaluation.
- Interpretation of results:
- practically nontoxic
- Remarks:
- Migrated information Criteria used for interpretation of results: other: Handbook of Toxicology (1957), W.S. Spector
- Conclusions:
- The test item LD50 is 5546 mg/kg for male rats. The test item results practically non-toxic.
- Executive summary:
After a fasting period of 16 days, the test item Parachlorbenzotrifluorid was administered by oral gavage to 10 male Wistar rats for each dose level (4000, 6300 and 10000 mg/kg b/w). The observed mortality 'til day 4 was as follows:
dose level 4000 mg/kg : 1/10 rats died
dose level 6300 mg/kg : 8/10 rats died
dose level 10000 mg/kg: 9/10 rats died
The registered clinical signs were: loss of balance and convulsions.
The LD50 was calculated by Probit analysis and was found to be 5546 mg/kg b/w.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 5 546 mg/kg bw
- Quality of whole database:
- The key study is no GLP compliant, but is of high quality (Klimisch score = 2)
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- April 1992
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP, in accordance with guidelines
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.2 (Acute Toxicity (Inhalation))
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: WISK (SPF71), Hoechst AG, Kastengrund
- Age at study initiation: 8-10 weeks
- Weight at study initiation: males: mean 191 g (range 186-195 g); females: mean 190 g (range 185-194 g).
- Fasting period before study:
- Housing: Macrolon cages Type 4, air-conditioned, with pellet wood floor, housed in groups of 5 animals.
- Diet (e.g. ad libitum): Altromin 1324 rodent food ad libitum
- Water (e.g. ad libitum): ad libitum, tap water in plastic bottles.
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2°C
- Humidity (%): 50± 20%
- Photoperiod (hrs dark / hrs light): 12 dark, 12 light h
IN-LIFE DATES: From: 1 April 1992 To: 15 April 1992 - Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose only
- Vehicle:
- clean air
- Details on inhalation exposure:
- The dry compressed air arrives in the 2 component nozzle up to the exposure tubes, with a flow of 800 L/h. The test item is injected with a constant speed.
- Analytical verification of test atmosphere concentrations:
- yes
- Remarks:
- gaschromatography equipped with FID detector
- Duration of exposure:
- ca. 4 h
- Concentrations:
- 32.03 mg /L air.
- No. of animals per sex per dose:
- 5 per each sex.
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations: twice a day. Weighing: day 8 and day 15
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight. - Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 32.03 mg/L air (analytical)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Mortality:
- No mortality was registered.
- Clinical signs:
- other: Increase of respiration rate, ataxia, irregular respiration, stupor, ruffled coat, stilted gait, ataxic gait, uncorrodinated gait, prone position, tremors, palpebral fissure narrow, increase of salivation.
- Body weight:
- Regular increase of bw in both male and female animals.
- Interpretation of results:
- practically nontoxic
- Remarks:
- Migrated information Criteria used for interpretation of results: expert judgment
- Conclusions:
- Based on this study results, the test item LC50 is > 32.03 mg/L air, after a 4 hours exposure. The test item results practically non toxic to rats.
- Executive summary:
Ten animals, 5 males and 5 females, were exposed to a nose-only inhalation treatment at a concentration of 32.03 mg/L air of p-Chlorbenzotrifluoride, for 4 hours. Clinical signs, body weights and mortality was observed and registered up to a post-exposure observation period of 14 days. No mortality was observed. The reported clinical signs comprised: increase of respiration rate, ataxia, irregular respiration, stupor, ruffled coat, stilted gait, ataxic gait, uncorrodinated gait, prone position, tremors, palpebral fissure narrow, increase of salivation. These clinical signs were fully reversible within 5 days. The body weight gain was regular. Based on this study ' results, the test item LC50 is > 32.03 mg/L air, after a 4 hours exposure. The test item results practically non toxic to rats.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating conc.
- Value:
- 32 032 mg/m³
- Quality of whole database:
- The key study is GLP compliant and it is of high quality (Klimisch score = 1)
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- March-April 1976
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: No GLP, no guidelines; liver function was the focal parameter
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- 6 rabbits were applied with a single dose of the test item on the shaved neck skin for 5 hours and observed for 7 days. Before the application and at day 1, 3 and 7, the activity of aspartate- and alanine aminotransfrase (AST and ALT) were measured in the peripheral blood. The survived animals were sacrificed at the end of the study and their liver was analyzed for hystologic abnormalities.
- GLP compliance:
- no
- Test type:
- other: liver functioning assessment after single dermal application
- Limit test:
- yes
- Species:
- rabbit
- Strain:
- Himalayan
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 1.5 - 2 kg
- Housing: in single cages and with a plastic collar allowing to avoid the oral contact with the treated skin area
IN-LIFE DATES: From: 29 march 1976 To: 6 april 1976 - Type of coverage:
- not specified
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- REMOVAL OF TEST SUBSTANCE
- Washing: with a sponge and cold water
- Time after start of exposure: 5 hours
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 5000 g - Duration of exposure:
- 5 h
- Doses:
- 5000 mg
- No. of animals per sex per dose:
- 6
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 7 days
- Frequency of observations and weighing: blood was collected and analysed for AST and ALT activity on days: 0, 1, 3 and 7
- Necropsy of survivors performed: yes
- Other examinations performed: mortality, beahviour, micro and macroscopic examination of the liver - Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- > 3 300 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality
- Clinical signs:
- No clinical sign reported
- Body weight:
- No data
- Gross pathology:
- No abnormality reported
- Other findings:
- After 24 hours the activities of of AST and ALT were slightly increased, but this effect was fully reversible whithin 7 days after the application.
- Interpretation of results:
- practically nontoxic
- Remarks:
- Migrated information Criteria used for interpretation of results: expert judgment
- Conclusions:
- Parachlorbenzotrifluorid exerted no adverse effect to rabbits after dermal application of 5000 mg for 5 hours. After 24 hours the activities of AST and ALT were slightly increased, but this effect was fully reversible whithin 7 days. No mortality, neither abnormal behaviour were observed during the 7 -days post-application period. No micro-, nor macroscopic findings were observed after hystological liver analysis.
- Executive summary:
6 rabbits were applied with a single dose of the test item on the shaved neck skin for 5 hours and observed for 7 days afterwards. Before the application and at day 1, 3 and 7, the activities of aspartate- and alanine aminotransfrase (AST and ALT) were measured in the peripheral blood. After 24 hours the activities of AST and ALT were slightly increased, but this effect was fully reversible whithin 7 days after the application. No mortality, neither abnormal behaviour were observed during the 7 -days period. The survived animals were sacrificed at the end of the study and their liver was analyzed for hystologic abnormalities. No micro-, nor macroscopic findigs were reported.
Reference
Liver functioning parameters before and after the test item dermal application
| AST | ALT | ||||||
| Initial value | t = 24 h | t = 3 d | t = 7 d | Initial value | t = 24 h | t = 3 d | t = 7 d |
n | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
mean | 4.7 | 14 | 5.3 | 2.3 | 31.3 | 57.5 | 41.7 | 31.7 |
S.D. | 2.1 | 4.7 | 1.2 | 0.5 | 4.0 | 10.3 | 5.1 | 4.1 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 3 300 mg/kg bw
- Quality of whole database:
- The two studies are non GLP and non-guideline compliant; however they together form a reliable weight of evidence.
Additional information
Even if the presented studies are quite old, the whole data base is deemed to be sufficient to satisfy the data requirements for the tonnage band 100 -1000 t/a, as information on all the route of exposure are available, showing an overall low acute toxicity of PCBTF to the test animals. The test species are in agreement with those indicated in the most recent test guidelines and therefore are relevant and adequate for the classification and the CSA.
Justification for selection of acute toxicity – oral endpoint
Lowest available LD50
Justification for selection of acute toxicity – inhalation endpoint
only key study available
Justification for selection of acute toxicity – dermal endpoint
The most ducumented study between the two available. However both studies coherently indicate that no adverse effect is observed after the dermal application of PCBTF to laboratory animals at doses of 2000 mg/kg bw and 3300 mg/kg bw (5000 mg applied to wors case rabbit of 1.5 kg bw).
Justification for classification or non-classification
The substance is not classified for acute toxicity because no effects because the acute oral LD50>2000 mg/kg and the acute inhalatory LC50> 32 mg/L and the dermal LD50>3300 mg/kg bw
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live1